🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Utah Medical Products, Inc. UTMD R2K

Healthcare · Medical Instruments & Supplies · United States
https://www.utahmed.com

Utah Medical Products, Inc. offers medical devices for the healthcare industry in the United States, Europe, and internationally. It offers fetal monitoring accessories, vacuum-assisted delivery systems, and other labor and delivery tools; DISPOSA-HOOD infant respiratory hoods; and DELTRAN PLUS blood pressure monitoring systems. The company provides GESCO, an umbilical vessel catheter, including DIALY-NATE disposable peritoneal dialysis sets; PALA-NATE silicone oral protection devices; URI-CATH urinary drainage systems; NUTRI-CATH\NUTRI-LOK feeding device; PICC-NATE, a percutaneous intraepithelial central venous catheter; MYELO-NATE lumbar sampling kits; HEMO-NATE disposable filters; and catheterization procedure tray of instruments and supplies. In addition, it offers LETZ system to excise cervical intraepithelial neoplasia and other lower genital tract lesions; loop, ball, and needle electrodes; FILTRESSE evacuators; other specialty electrodes and supplies and gynecologic tools; Femcare trocars, cannulae, laparoscopic instruments, and accessories; and EPITOME and OptiMicro electrosurgical devices. Further, the company provides Filshie Clip female surgical contraception devices; PATHFINDER PLUS, an endoscopic irrigation device; suprapubic catheterization products; LIBERTY, a urinary incontinence treatment and control system; ENDOCURETTE, a curette for uterine endometrial tissue sampling; TVUS/HSG-Cath to assess abnormal or dysfunctional uterine bleeding and other abnormalities of uterus; and LUMIN, a tool to manipulate the uterus in laparoscopic procedures. Additionally, it offers DELTRAN, a disposable pressure transducer; BioPharm HP-PRT; and pressure monitoring accessories, components, and other molded parts. It serves neonatal intensive care units, labor and delivery departments, women's health center in hospitals, outpatient clinics, and physician's offices. The company was incorporated in 1978 and is headquartered in Midvale, Utah.

READ MORE ›
$66.45
+23.17% 1Y

Market & Price

Market Cap
$211.58M
Current Price
$66.45
High / Low (52W)
$70.65 / $52.83
Beta
0.37

Valuation

Stock P/E
19.66
Industry PE
23.65
Forward P/E
-
PEG Ratio
4.25
Book Value
$37.43
Price to Book
1.78
P/S
5.64
EV/EBITDA
8.18
Dividend Yield
1.87%

Profitability & Returns

ROCE
9.51%
ROE
9.14%
ROA
6.22%
Profit Margin
28.91%
Op Margin
34.47%
EPS (Latest Qtr)
$0.82
EPS (TTM)
$3.38

Balance Sheet & Liquidity

Debt/Equity
0.17
Quick Ratio
25.98
Current Ratio
28.64
Debt
$210.00K
Total Assets
$122.54M
Current Assets
$97.74M
Working Capital
$95.14M

Ownership

Promoter Holding
7.18%
Chg in Prom Hold
-
FII / Inst Holding
74.75%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$124.38M
Total Revenue (TTM)
$37.53M
EBITDA
$15.21M
Free Cash Flow
$10.04M
Operating Cash Flow
$13.34M
Shares Outstanding
3.18M
Gross Margin
57.94%
Payout Ratio
36.39%

Growth (CAGR)

Revenue 5Y
-9.68%
Profit 5Y
-11.84%
Revenue (YoY)
-10.20%
Earnings (YoY)
-11.00%

PROS

  • Excellent profit margin of 28.9%.
  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Revenue declined at -9.7% CAGR over 5 years.
  • Earnings shrank at -11.8% CAGR over 5 years.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 UTMD Utah Medical Products, Inc. R2K 66.45 19.66 $211.58M 1.87% 9.51% 9.14% -9.68% -11.84%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue ---10.26M10.83M10.12M10.20M10.89M10.96M10.39M9.76M10.73M11.85M12.49M11.83M10.90M8.79M10.48M12.01M10.96M12.60M12.57M12.91M12.32M13.43M12.96M13.57M12.52M12.87M12.51M12.33M11.34M10.40M10.01M9.16M9.71M9.95M9.81M9.04M8.72M
Cost of Revenue -----------------------------------4.17M4.36M4.21M3.78M3.44M
Gross Profit 6.22M6.25M5.78M6.54M6.89M6.50M6.47M6.92M6.98M6.29M6.11M6.77M7.50M7.38M7.81M6.84M4.95M6.50M7.26M6.95M7.79M8.07M8.11M7.53M8.15M8.19M8.33M7.84M7.74M7.36M7.10M6.77M6.25M5.80M5.32M5.54M5.59M5.60M5.26M5.28M
Operating Expenses -----------------------------------2.07M2.40M2.99M2.82M2.28M
Operating Income 4.31M4.32M3.94M4.72M5.03M4.68M-4.97M5.06M4.40M-4.10M4.48M4.37M-3.86M1.98M3.59M-3.89M4.76M5.10M-4.52M5.06M5.14M-4.44M4.42M3.97M-3.88M3.44M3.34M-3.47M3.20M2.61M2.44M3.01M
EBITDA -----------------------------------4.19M3.95M3.38M3.20M3.69M
Interest Expense ----------------------------------------
Pretax Income -----------------------------------3.86M3.84M3.31M3.11M3.18M
Tax Provision -----------------------------------817.00K788.00K678.00K540.00K578.00K
Net Income -----------------------------------3.04M3.05M2.63M2.57M2.60M
Diluted EPS 0.850.860.780.951.040.97-0.671.091.151.800.910.840.940.991.170.840.360.800.940.830.941.151.130.961.121.181.251.161.151.081.181.090.981.030.860.920.940.820.800.82
R&D Expense 110.00K119.00K135.00K118.00K119.00K103.00K-113.00K117.00K108.00K-115.00K113.00K130.00K-135.00K116.00K125.00K-130.00K128.00K127.00K-123.00K135.00K112.00K-144.00K133.00K138.00K-266.00K255.00K172.00K-154.00K135.00K167.00K-154.00K

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -------39.30M41.41M42.00M46.90M42.18M49.05M52.28M50.22M40.90M38.52M
Cost of Revenue -------------20.09M20.19M16.76M16.52M
Gross Profit 13.79M13.21M22.40M25.31M24.27M24.98M24.18M23.69M26.39M26.31M29.47M25.55M30.92M32.20M30.04M24.14M22.00M
Operating Expenses -------------12.41M13.26M10.55M10.60M
Operating Income 9.43M8.92M11.84M15.20M14.83M16.20M15.65M16.19M19.01M18.70M17.63M13.71M18.88M19.79M16.78M13.59M11.40M
EBITDA -------------26.87M23.14M16.44M14.41M
Interest Expense -----------------
Pretax Income -------------20.66M20.09M16.80M14.11M
Tax Provision -------------4.19M3.45M2.93M2.82M
Net Income -------------16.47M16.64M13.87M11.29M
Diluted EPS 1.721.652.032.743.023.023.143.222.284.953.942.944.044.524.573.963.48
R&D Expense 361.00K397.00K-518.00K563.00K491.00K460.00K522.00K475.00K447.00K454.00K483.00K486.00K526.00K493.00K560.00K813.00K668.00K

Compounded Sales Growth

5 Years:-9.68%
1 Year:-10.20%

Compounded Profit Growth

5 Years:-11.84%
1 Year:-11.00%

Stock Price Performance

1 Year:+23.17%
6 Months:+20.03%
3 Months:+0.25%
1 Month:+2.18%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --41.24M76.39M76.94M80.71M81.08M79.17M76.19M92.75M99.77M109.79M111.75M-123.87M135.46M122.54M122.54M
Current Assets --------------89.92M106.27M96.33M97.74M
Cash & Equivalents 97.00K410.00K3.82M6.53M8.87M14.39M19.27M23.28M26.30M39.88M51.11M42.79M51.59M-75.05M92.87M82.98M85.76M
Inventory --------------8.81M9.58M8.81M7.93M
Receivables --------------5.54M3.49M4.24M4.04M
Total Liabilities --3.45M35.63M25.96M20.13M16.52M9.53M6.95M14.62M10.78M8.69M8.92M-9.62M7.14M5.11M3.27M
Current Liabilities --1.90M9.63M7.82M7.61M8.97M4.07M3.02M5.28M5.26M3.45M3.79M-5.96M4.71M3.76M2.60M
Long Term Debt -----9.00K5.07K1.01K-0000-----
Total Debt --------------341.00K295.00K282.00K225.00K
Total Equity --37.79M40.76M50.97M60.58M64.56M69.65M69.24M78.12M88.99M101.09M102.82M-114.25M128.31M117.43M119.27M
Shares Outstanding --------------3.63M3.63M3.34M3.19M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 7.23M7.16M11.37M13.56M12.31M15.39M13.80M14.53M16.91M16.83M17.06M20.14M-21.15M22.28M14.83M14.69M
Investing Cash Flow -3.16M2.71M-26.68M-208.00K-344.00K-1.13M-246.00K-3.30M-1.60M534.00K-21.54M-860.00K--818.00K-639.00K-208.00K-371.00K
Financing Cash Flow -3.77M-6.42M18.08M-11.17M-6.60M-8.26M-8.89M-6.34M-2.65M-4.78M-4.23M-10.73M--5.48M-4.17M-23.84M-12.34M
Capital Expenditure -466.00K-1.53M-247.00K-254.00K-339.00K-1.11M-176.00K-3.29M-1.60M-402.00K-540.00K-860.00K--818.00K-639.00K-235.00K-371.00K
Free Cash Flow 6.76M5.62M11.12M13.31M11.97M14.28M13.62M11.23M15.31M16.43M16.52M19.28M-20.33M21.64M14.60M14.32M
Net Change in Cash -------------14.85M17.48M-9.21M1.98M
Share Buybacks --------01.21M398.00K6.98M02.50M019.97M8.36M
Dividends Paid 3.34M6.03M3.43M3.56M3.67M3.77M3.85M3.92M2.96M4.03M4.11M4.12M11.46M3.16M4.28M4.26M3.98M

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------60.3%63.7%62.6%62.8%60.6%63.0%61.6%59.8%59.0%57.1%
Operating Margin % -------41.2%45.9%44.5%37.6%32.5%38.5%37.9%33.4%33.2%29.6%
Net Margin % -------------31.5%33.1%33.9%29.3%
ROE % -------------14.4%13.0%11.8%9.5%
ROCE % -22.7%17.7%22.0%20.3%22.5%20.8%22.1%21.7%19.8%16.6%12.7%-16.8%12.8%11.4%9.5%

Shareholding Pattern

Insiders
7.18%
Institutions
74.75%
Public Float
80.53%

Top Institutional Holders

#Holder% HeldSharesValue
1 Brandes Investment Partners L.P. 14.11% 449.28K $29.85M
2 Dimensional Fund Advisors LP 6.22% 197.91K $13.15M
3 Blackrock Inc. 5.89% 187.65K $12.47M
4 Renaissance Technologies, LLC 5.78% 184.11K $12.23M
5 Vanguard Capital Management LLC 4.35% 138.56K $9.21M
6 Geode Capital Management, LLC 3.77% 120.10K $7.98M
7 Minerva Advisors LLC 2.94% 93.61K $6.22M
8 Hotchkis & Wiley Capital Management, LLC 2.80% 89.13K $5.92M
9 Rice, Hall, James & Associates LLC 2.13% 67.88K $4.51M
10 State Street Corporation 2.02% 64.40K $4.28M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for UTMD

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks